Evaluation of NPP1 as a novel biomarker of coronary artery disease: A pilot study in human beings by Mohammadpour, A.H. et al.
  
*Corresponding author: Sepideh Elyasi, Tel: +98 51 31801588, Fax: +98 51 38823251, Email: Elyasis@mums.ac.ir 
©2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits 
unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from 
the authors or the publishers. 
Adv Pharm Bull, 2018, 8(3), 489-493 
doi: 10.15171/apb.2018.057 
http://apb.tbzmed.ac.ir 
Advanced  
Pharmaceutical  
Bulletin 
Evaluation of NPP1 as a Novel Biomarker of Coronary Artery Disease: 
A Pilot Study in Human Beings 
Amir Hooshang Mohammadpour1,2 , Saeed Nazemi3, Fatemeh Mashhadi2, Atefeh Rezapour2, Mohammad 
Afshar4,5, Sepideh Afzalnia3, Afsaneh Mohammadi3, Hamid Reza Mashreghi Moghadam6, Maryam Moradian7, 
Seyed Mohammad Hasan Moallem8, Saeed Falahaty2, Azadeh Zayerzadeh2, Sepideh Elyasi1,2*   
1 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 
2 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 
3 Research and Education Department, Razavi Hospital, Mashhad, Iran. 
4 Department of Anatomy, Birjand University of Medical Sciences, Birjand, Iran. 
5 Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 
6 Birjand Cardiovascular Disease Research Center; Department of Cardiology, Birjand University of Medical Sciences, Birjand, Iran. 
7 Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Center, Tehran, Iran. 
8 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction
Vascular calcification is a life threatening complication 
of cardiovascular disease and an independent risk factor 
for high morbidity and mortality.1 It is an inevitable 
process particularly in the advanced stages of 
atherosclerosis which can cause the plaque rupture. 
Coronary artery calcification (CAC) is a surrogate 
marker for subclinical atherosclerosis and recently 
determined as strong predictor that comforts the 
prediction of future cardiovascular events particularly in 
intermediate risk subjects. It is determined by electron 
beam-computed tomography (EBCT).2 Increased 
coronary artery calcium score (CACS) correlates with 
the risk of cardiovascular disease.3  
Recent studies have provided impetus to shift from 
cellular interaction based calcification models to models 
emphasizing on the important role of extracellular matrix 
in calcification. Adenosine triphosphate (ATP) and other 
nucleotides and nucleosides play different biochemical 
roles depending on differential tissue expression, cell 
distribution, and substrate availability and their presence 
in either the intracellular or extracellular compartment. 
Ecto-nucleotidases classified to four families including 
ecto-nucleotide pyrophosphate / phosphor - diesterase 
(ENPP) family. ENPP1 is a member of ENPP family 
that expresses in different tissues including cartilage, 
kidney, heart, parathyroid and skeletal muscle, and to a 
greater extent in vascular smooth muscle cells (VSMCs), 
osteoblasts and chondrocytes.4-6 NPP1 is known to play 
vital roles in calcium/phosphate regulation, and repression 
of soft tissue mineralization, and maintaining skeletal 
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Abstract 
Purpose: Coronary artery calcification (CAC) is utilized as an important tool for 
global risk assessment of cardiovascular events in individuals with intermediate risk.  
Ecto phosphodiesterase/nucleotide phosphohydrolase-1(ENPP1) converts extracellular 
nucleotides into inorganic pyrophosphate and it is a key regulator of tissue calcification 
that adjusts calcification in tissues like vascular smooth muscle cells. The main 
purpose of this clinical study was to find out the correlation between ENPP1 serum 
concentration and CAC in human for the first time. 
Methods: In this study 83 patients (16 diabetic patients and 67 non-diabetic patients) with 
coronary artery disease who fulfilled inclusion and exclusion criteria, entered the study. For 
all patients a questionnaire consisting demographic data and traditional cardiovascular risk 
factors were completed. Computed tomography (CT)-Angiography was carried out to 
determine coronary artery calcium score and enzyme-linked immunosorbent assay (ELISA) 
method was used for measuring ENPP1 serum concentrations.  
Results: There was a reverse significant correlation between ENPP1 serum concentration 
and total CAC score and also CAC of right coronary artery (RCA) (P<0.05) in non-diabetic 
patients.  
Conclusion: On the basis of our results, ENPP1 serum concentration may be a suitable 
biomarker for coronary artery disease at least in non-diabetic patients. However, more 
studies with higher sample size are necessary for its confirmation. 
Research Article 
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structure and function. NPP1 hydrolyses ATP to produce 
either inorganic pyrophosphate (PPi) plus adenosine 
monophosphate (AMP) or inorganic phosphate (Pi) 
plus adenosine diphosphate (ADP) in a two stage 
process via either ADP or a phosphate bound 
intermediate.7-9 PPi is a central regulator of calcification 
in the extracellular matrix. In extracellular, PPi draw ups 
gene expression and cellular differentiation, which have 
main physiologic effects on chondrogenesis and 
expression of osteopontin. PPi strongly inhibits the 
nucleation and advancement of hydroxyapatite (HA) and 
other basic calcium phosphate crystals.7,10,11 Therefore, 
through generating PPi, NPP1 is a key regulator of tissue 
calcification and bone development and can be effective in 
prevention of pathologic tissue calcification.  
According to this, we evaluated the ENPP1 as a 
diagnostic biomarker in human to determine the extent of 
coronary artery calcification. 
 
Materials and Methods 
Patients 
Eighty-three patients, who aged higher than 40 years old 
with diagnosis of coronary artery disease by angiography 
which was performed by the cardiologist, were enrolled 
in this study between November 2015 and March 2016. 
This test is the best way to detect coronary artery disease 
(CAD) in the arteries, over 51% of which are blocked by 
atherosclerotic plaques and useful in detecting the 
vessels responsible for advanced CAD. However, it does 
not provide information about the artery wall and 
atherosclerosis may not be diagnosed that has not yet 
captured the duct.12 patients with >50% coronary 
stenosis of at least one artery were considered as CAD+ 
and included in study. Patients were recruited from 
Cardiology ward of Razavi Hospital, Mashhad, Iran. 
This study was accepted by ethics committee of 
Mashhad University of Medical Sciences (code: 
931459). All patients signed the consent form prior to 
entry in the study. All patients signed the consent form 
prior to entry in the study. 
Patients with calcium and phosphor metabolic disorder 
or receiving medications which are effective on calcium 
and/or phosphate and immunosuppressant or antioxidant 
medications, intake of folic acid and methotrexate, 
malignancies, heart failure, hypo or hyper 
parathyroidisim, renal insufficiency, history of 
osteoarticular disorders and chronic inflammatory 
diseases, and acute infection during the study were 
excluded from the study. A questionnaire containing 
demographic data, laboratory data, drug and medical and 
familial history of cardiovascular risk factors was 
completed for all patients.  
 
Determination of ENPP1 serum concentration and CAC 
Twenty milliliter of whole blood was collected from 
patients and centrifuged at 2500 rpm for 10 min. Two 
milliliter serum were isolated and divided into 4 micro 
sets of 0.5 ml. The serum was stored at -70 °C until 
required for analysis. Routine biochemical measurements 
such as plasma glucose, total cholesterol (TC), 
triglycerides, low density lipoprotein Cholesterol (LDL-c), 
high-density lipoprotein cholesterol (HDL-c), and serum 
calcium and phosphorus level were carried out by routine 
laboratory methods. Serum level of soluble ENPP1 was 
measured with an enzyme-linked Immunosorbant assay 
(ELISA) -kit (Zellbio, Germany); each assay was 
calibrated using ENPP1 standard curve following the 
manufacturer‘s instructions. Coronary Artery 
Calcification score of left main coronary artery (LMCA), 
left anterior descending (LAD) and circumflex (CX) and 
right coronary artery (RCA) was determined by high 
resolution B mode ultrasonography in radiology 
department of Razavi Hospital. CAC measurement is 
now considered a potentially useful test for improving 
coronary risk assessment in selected intermediate-risk 
asymptomatic patients in whom high CAC scores signify 
increased cardiovascular risk beyond that predicted by 
conventional cardiovascular risk factors alone. Agatston 
score is a semi-automated tool to calculate a score based 
on the extent of coronary artery calcification detected by 
an unenhanced low-dose CT scan which is routinely 
performed in patients undergoing cardiac CT. Due to an 
extensive body of search, it allows for an early risk 
stratification as patients with a high Agatston score 
(>160) have an increased risk for a major adverse cardiac 
event. Although it does not allow for the assessment of 
soft non-calcified plaques, it has shown a good 
correlation with contrast enhanced CT coronary 
angiography.13,14  
However, it should be defined that when the pretest 
probability of coronary artery disease is low (eg, 
asymptomatic screening setting), a CAC score of zero is 
associated with low risk of coronary artery disease and 
low risk of near-term coronary events but in older 
asymptomatic patients with risk factors, CAC=0 is 
associated with a moderate increased risk of events and 
in patients with clinical signs and symptoms associated 
with an intermediate-to-high risk of coronary disease, 
CAC=0 is often associated with myocardial ischemia on 
provocative testing and with a high risk of near-term 
coronary events.15 
 
Statistical Analysis 
Data recruited from the standard forms were gathered and 
then analyzed with SPSS version 16.0 (Systat Software, 
Inc., Chicago, IL). For descriptive assessment, mean ± 
standard deviations of continuous variables were provided. 
For nominal variables, number and percentages were 
reported. Correlation between Serum Concentration of 
ENPP1 with CAC was analyzed using spearman 
correlation test. Chi-squared test and t test were applied 
for continuous and nominal data, where appropriate. 
Results were considered significant at p<0.05. 
 
Results 
Characteristics of the study Population  
The study population consists of 83 patients, male (77%) 
and female (23%). The mean age of population was 
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56.80±10.73 years. Patients’ characteristics, laboratory 
tests including biochemical parameters, and traditional 
cardiovascular risk factors and mean ENPP1 serum level 
are summarized in Table 1. Moreover, these factors are 
defined in diabetic and non-diabetic patients separately 
and female/male ratios, positive family history of CAD 
and hypertension prevalence were significantly different 
between these two groups. 
 
Table 1. patients characteristic, laboratory data, traditional cardiovascular risk factors and mean ENPP1 serum level of patients 
Patients characteristic 
All patients (n=83) 
(Mean±SD) 
Diabetic patients (n=16) 
(Mean±SD) 
Non-diabetic patients (n=67) 
(Mean±SD) 
P value 
Age (year) 57.13±10.7 56.4±10.52 57.74±10.65 0.951 
BMI (kg/m2 ) 28.36±4.78 28.46±3.8 27.99±5.46 0.431 
Female/male ratio 0.29 0.54 0.32 0.005*2 
Laboratory tests Mean±SD    
HDL-C (mg/dl) 41.92±9.97 40.76±9.14 45.24±15.68 0.661 
LDL-C (mg/dl) 90.81±29.14 95.88±34.56 88.69±28.04 0.061 
Total cholesterol (mg/dl) 163.30±33.32 165.76±38.28 164±33.81 0.091 
FBS (mg/dl) 104.56±24.00 141.2±44.05 97.57±14.71 0.005*1 
Traditional risk factors Frequency (%)    
Hypertension (%) 45.88 60 45.34 0.005*2 
Dyslipidemia (%) 63.52 65 61.62 0.632 
Positive family history (%) 51.76 47.62 62.79 0.005*2 
Diabetes (%) 20.58 100 0 - 
Current Smoking (%) 35.29 33.33 23.25 0.662 
Concentration of ENPP1 
(pg/mL) 
106.4214±78.54876 132.62±100.5 100.26±71.97 0.141 
BMI: Body Mass Index, HDL-C: High Density Lipoprotein-Cholesterol, LDL-C: Low Density Lipoprotein-Cholesterol, FBS: Fast Blood 
Sugar, ENPP1: Ecto-nucleotide pyrophosphate/phosphor-di-esterase 
1 independent sample T test 2chi square 
* P value<0.05 is considered significant 
 
Correlation between ENPP1 serum level and Coronary 
Artery Calcification agatson score  
There was a reversed significant correlation between 
ENPP1 serum level and total coronary artery 
calcification score and CAC score of RCA in non-
diabetic patients (P<0.05) but, there was no significant 
correlation between ENPP1 serum level and CAC score 
of LMCA, LAD and CX.(p>0.05) (Table 2) 
 
Table 2. Correlation between ENPP1 serum concentration with LAD, RCA, LMCA, and CX coronary artery calcification score 
Coronary artery Calcium score Mean ±SD P value Spearman Correlation Test Correlation coefficient 
Total calcification of coronary vessels (agatson score) 357.29±590.81 0.004 -0.121 
Calcification in coronary LAD (agatson score) 184.60±304.46 0.345 0.044 
Calcification in coronary RCA (agatson score) 63.37±101.86 0.00 -0.22 
Calcification in coronary CX (agatson score) 44.86±99.00 0.416 -0.264 
Calcification in coronary LMCA (agatson score) 34.11±116.00 0.494 -0.107 
CAC: Coronary Artery Calcification, LAD: Left Anterior Descending, RCA: Right Coronary Artery LMCA: Left Main Coronary Artery, CX: 
Circumflex 
 
Moreover, based on Rumberger method we divided 
patients based on their total CAC to three groups; mild 
(CAC lower than 25th of range), moderate (between 25th 
and 75th of range) and severe (≥75th of CAC range). 
Fifty-four percent of the patients were in mild group and 
44.4% and 1.6% were in moderate and severe groups, 
respectively. There was no significant difference 
between ENPP1 serum level of these groups (P>0.05).  
 
Discussion 
In this study, the correlation of the ENPP1 serum level 
with CAC was evaluated for the first time in human. As 
mentioned in results, there was a significant reversed 
correlation between ENPP1 serum level and total and 
RCA CAC score in non-diabetic patients (P<0.05) but no 
significant correlation with CAC score of LAD, LM and 
CX (P ≥0.05). Several In vitro and In vivo studies have 
been conducted on the relationship between coronary 
artery calcification and serum ENPP1 level previously 
but they were only limited to the examination of genetic 
disorders and gene mutations of ENPP1 in infants and 
evaluation of the relationship between serum levels of 
ENPP1 and calcification of atherosclerotic plaques in 
diabetic patients. 
Based on previous studies, it is entirely apparent that the 
calcification is suppress by ENPP1 by means of PPi that 
it is a potent inhibitor of hydroxyl apatite (HA) crystal 
formation in mineralized competent of tissues. 
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NPPs can convert AMP into adenosine and Pi, although 
conflicting reports suggest that AMP competitively 
inhibits NPP activity. PPi is hydrolyzed by tissue-
nonspecific alkaline phosphatase (TNAP) into inorganic 
phosphate (Pi), which co-crystallizes with calcium into 
HA and thereby promotes bone formation. Thus, PPi has 
a dual role as it can both suppress and promote HA 
crystal deposition, depending on the expression ratio and 
catalytic activities of NPP1 and TNAP. The distorted 
balance of Pi/PPi ultimately leads to pathological 
calcification.16-19 In another study, NPP1-deficient mice 
showed reduced levels of extracellular PPi, causing 
pathological calcification of cartilage and soft tissues, 
such as arterial smooth muscle walls and also abnormal 
bone development.16,17 So, according to the previous 
studies, it is clear that NPP1 and PPi physiologically 
work to prevent calcification of arteries and certain other 
soft tissues.20,21 This study was the first clinical study that 
evaluated the relationship between serum concentrations 
of ENPP1 and coronary artery calcification in patients 
with chronic heart ischemia. According to the results 
mentioned above, there was a significant reversed 
relationship between the coronary artery calcification and 
this biomarker in non-diabetic patients. 
A study was conducted in 2010 by Jeong et al. which 
assessed the relationship between coronary artery 
calcification and ENPP1 gene expression levels in 140 
diabetic patients. None of patients had history of 
cardiovascular disease and no relationship was found 
between coronary artery calcification and ENPP1 gene 
expression levels.22 In present study 16 diabetic patients 
and 67 non-diabetic patients were included and no 
relationship was found between total coronary artery 
calcification score and serum concentrations of ENPP1. 
However, after exclusion of diabetic patients a 
significant relationship was observed (P = 0.004). 
Nowadays type 2 diabetes prevalence is increasing 
steadily all over the world. One of the criteria for type 2 
diabetes, is insulin resistance in different body tissues 
such as skeletal muscle, liver and fat tissues that occurs 
due to impaired peripheral receptor signaling of insulin. 
In several studies it has been observed that ENPP1, 
which is connected directly to the insulin receptor α, 
impairs receptor function and then reduces the signaling 
cascade, in a wide variety of tissues such as skeletal 
muscle and liver.23 In some other studies has been 
observed that the expression level of ENPP1 in patients 
with insulin resistance has been increased and also it is 
mentioned that regulatory increased ENPP1level in rat 
liver, induces insulin resistance and glucose tolerance.24-26 
In a multicenter clinical study conducted in Italy and 
America in 2005, it is observed that increased expression 
of ENPP1 is associated with a higher prevalence of 
diabetes and myocardial infarction.27 So, in this research, 
we excluded patients with type 2 diabetes and it was 
found that the level of serum ENPP1 is affected by type 
2 diabetes and there is a significant negative relationship 
between the ENPP1 serum levels and the total 
calcification score of coronary arteries in non-diabetic 
patients with cardiovascular disease.  
This significant negative correlation was also found by 
CAC of RCA but not the other coronary arteries. It may 
be due to non-uniform distribution of other vessels’ 
calcium scores resulting from small sample size. So, 
limited number of patients included in this study is the 
major limitation of this study.  
 
Conclusion  
In this study, the correlation of the ENPP1 serum level 
with CAC was clinically evaluated for the first time in 
patients with coronary artery disease. There was a 
reverse significant correlation between ENPP1 serum 
level and total CAC and CAC of RCA in non-diabetic 
patients (P<0.05), but there was no significant correlation 
between ENPP1 serum level patients and LAD, LM and 
CX (P >0.05). Further studies are recommended in this 
field with higher sample size.  
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